Grandfield & Dodd’s AbbVie ABBV Stock Holding History

Grandfield & Dodd’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.34M	Buy	6,153 +567	+10%	+$126K	0.08%	101
2025 Q4	$1.28M	Sell	5,586 -121	-2%	-$27.6K	0.07%	104
2025 Q3	$1.32M	Hold	5,707	–	–	0.08%	102
2025 Q2	$1.06M	Buy	5,707 +175	+3%	+$32.5K	0.06%	105
2025 Q1	$1.16M	Hold	5,532	–	–	0.07%	102
2024 Q4	$983K	Hold	5,532	–	–	0.06%	109
2024 Q3	$1.09M	Sell	5,532 -300	-5%	-$56K	0.06%	107
2024 Q2	$1M	Sell	5,832 -14	-0.2%	-$2.32K	0.06%	107
2024 Q1	$1.06M	Sell	5,846 -49	-0.8%	-$8.45K	0.07%	108
2023 Q4	$914K	Hold	5,895	–	–	0.06%	108
2023 Q3	$879K	Sell	5,895 -17	-0.3%	-$2.5K	0.06%	107
2023 Q2	$797K	Hold	5,912	–	–	0.06%	116
2023 Q1	$942K	Hold	5,912	–	–	0.07%	107
2022 Q4	$955K	Sell	5,912 -3	-0.1%	-$460	0.07%	105
2022 Q3	$790K	Hold	5,915	–	–	0.06%	104
2022 Q2	$910K	Hold	5,915	–	–	0.07%	104
2022 Q1	$960K	Buy	5,915 +818	+16%	+$119K	0.07%	103
2021 Q4	$690K	Sell	5,097 -486	-9%	-$57.4K	0.04%	120
2021 Q3	$600K	Buy	5,583 +300	+6%	+$34.3K	0.04%	123
2021 Q2	$600K	Sell	5,283 -219	-4%	-$24.7K	0.04%	122
2021 Q1	$600K	Hold	5,502	–	–	0.04%	121
2020 Q4	$590K	Sell	5,502 -60	-1%	-$5.77K	0.05%	119
2020 Q3	$490K	Hold	5,562	–	–	0.04%	122
2020 Q2	$550K	Buy	5,562 +275	+5%	+$24.2K	0.05%	118
2020 Q1	$403K	Buy	5,287 +351	+7%	+$29.9K	0.05%	127
2019 Q4	$437K	Sell	4,936 -375	-7%	-$31.1K	0.04%	136
2019 Q3	$402K	Buy	5,311 +350	+7%	+$24K	0.04%	136
2019 Q2	$361K	Sell	4,961 -404	-8%	-$31.8K	0.04%	144
2019 Q1	$432K	Sell	5,365 -429	-7%	-$35.1K	0.05%	136
2018 Q4	$534K	Sell	5,794 -1,167	-17%	-$103K	0.06%	115
2018 Q3	$658K	Sell	6,961 -1,093	-14%	-$104K	0.07%	116
2018 Q2	$746K	Sell	8,054 -1,173	-13%	-$115K	0.08%	107
2018 Q1	$873K	Sell	9,227 -3,383	-27%	-$372K	0.1%	99
2017 Q4	$1.22M	Sell	12,610 -287	-2%	-$27K	0.13%	88
2017 Q3	$1.15M	Hold	12,897	–	–	0.13%	89
2017 Q2	$935K	Hold	12,897	–	–	0.11%	96
2017 Q1	$840K	Hold	12,897	–	–	0.1%	102
2016 Q4	$808K	Buy	12,897 +643	+5%	+$39.2K	0.1%	101
2016 Q3	$773K	Buy	12,254 +222	+2%	+$14.4K	0.1%	99
2016 Q2	$745K	Sell	12,032 -314	-3%	-$19.1K	0.1%	95
2016 Q1	$705K	Hold	12,346	–	–	0.1%	93
2015 Q4	$731K	Sell	12,346 -177	-1%	-$10.2K	0.11%	92
2015 Q3	$681K	Buy	12,523 +250	+2%	+$16.3K	0.11%	93
2015 Q2	$825K	Buy	12,273 +1,072	+10%	+$70K	0.13%	89
2015 Q1	$656K	Buy	11,201 +217	+2%	+$13.1K	0.1%	94
2014 Q4	$719K	Sell	10,984 -107	-1%	-$6.75K	0.11%	92
2014 Q3	$641K	Buy	11,091 +357	+3%	+$19.8K	0.1%	99
2014 Q2	$606K	Sell	10,734 -90	-0.8%	-$4.72K	0.09%	108
2014 Q1	$556K	Buy	10,824 +706	+7%	+$35.7K	0.09%	113
2013 Q4	$534K	Hold	10,118	–	–	0.09%	111
2013 Q3	$453K	Hold	10,118	–	–	0.08%	115
2013 Q2	$418K	Buy	+10,118	New	+$443K	0.08%	116

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Grandfield & Dodd's ABBV Position: Q1 2026 in Review

Grandfield & Dodd increased its AbbVie (ABBV) stake by 10% in Q1 2026, buying an estimated $126K and bringing the position to 6,153 shares worth $1.34M. The position accounts for 0.08% of the portfolio, ranked #101.

Grandfield & Dodd first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Grandfield & Dodd held 6,153 shares of AbbVie worth $1.34M as of Q1 2026.
Grandfield & Dodd bought 567 AbbVie shares in Q1 2026, an estimated $126K.
AbbVie made up 0.08% of Grandfield & Dodd's portfolio in Q1 2026, its #101 holding.
Grandfield & Dodd first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Grandfield & Dodd's 13F filing for Q1 2026, filed 7 May 2026.